BROOKS LABORATORIES Share Price
BROOKS LABORATORIES Share Price Today
As of 14 Aug 2026, BROOKS LABORATORIES share price is ₹65.60. The stock opened at ₹62.50, compared to its previous close of ₹62.48. During today's trading session, BROOKS LABORATORIES share price moved in the range of ₹62.50 to ₹65.60, with an average price of ₹64.05 for the day. Looking at its last 52-week, the stock has touched a low of ₹36.30 and a high of ₹164.02. On the performance front, BROOKS LABORATORIES share price has declined by 13.47% over the last six months and is down 58.01% on a year-on-year basis.
BROOKS LABORATORIES Returns Calculator
About BROOKS LABORATORIES
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company working on a contract basis. The Company’s segment is Pharmaceutical products, including ingredients and intermediaries. It manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup, and eye/ear drops. Its products under the Carbapenem category are Imipenem 250 (Milligram) mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, and Doripenem 500mg. It offers Penicillins in the form of injections, tablets, and dry syrup. Its general category of products includes liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, Iron sucrose 50mg/2.5ml, Phenytoin sodium 50mg/ml and others. Its dry powder injections include Artesunate 60mg, Artesunate 120mg, Omeprazole 40mg, Rabeprazole 20mg, Pantoprazole 40mg and others.
BROOKS LABORATORIES Financial Highlights
- Revenue: BROOKS LABORATORIES reported revenue of ₹86.91 crore in FY26 vs ₹83.44 crore in FY25. It showed an increase of 4.16% on a yearly basis.
- Operating Profit: BROOKS LABORATORIES reported an operating profit of ₹24.58 crore in FY26 vs ₹9.79 crore in FY25. It showed an increase of 351.07% on a year-on-year basis.
- Net Profit: BROOKS LABORATORIES reported a net profit of ₹24.58 crore in FY26 vs ₹9.97 crore in FY25. It showed an increase of 346.54% on a yearly basis.
BROOKS LABORATORIES Quarterly Result Highlights
- BROOKS LABORATORIES reported revenue of ₹20.65 crore in Mar 2026, compared with ₹16.70 crore in Dec 2025, representing an increase of 23.65% on a quarter-on-quarter (QoQ) basis.
- BROOKS LABORATORIES reported an operating profit of ₹1.52 crore in Mar 2026, compared with ₹5.50 crore in Dec 2025, representing a decrease of 72.36% on a quarter-on-quarter (QoQ) basis.
- BROOKS LABORATORIES reported a profit of ₹1.52 crore in Mar 2026, compared with ₹5.50 crore in Dec 2025, reflecting a decrease of 72.36% on a QoQ basis.
- The earnings per share (EPS) of BROOKS LABORATORIES stood at ₹3.72 during Mar 2026.
| Sep 2025 | 0.01% |
|---|---|
| Dec 2025 | 0.09% |
| Mar 2026 | 0.17% |
| Jun 2026 | 0.00% |
BROOKS LABORATORIES Shareholder Returns
BROOKS LABORATORIES Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,64,271.00 | 38.32 | 5.56 | 13.74% | 0.61 | 17.33% | 93.24 | 0.83% | 0.48 | 10.90 |
| Divis Laboratories | 2,26,843.00 | 77.55 | 13.53 | 15.32% | 0.00 | 19.56% | 629.49 | 0.35% | 0.55 | 98.19 |
| Torrent Pharmaceuticals | 1,86,000.00 | 86.27 | 22.12 | 25.49% | 1.69 | 13.85% | 222.76 | 0.69% | 0.49 | 58.70 |
| Zydus Lifesciences | 1,20,099.00 | 26.15 | 4.43 | 18.59% | 0.31 | 17.35% | 237.30 | 0.08% | 0.33 | 35.38 |
| Cipla | 1,18,027.00 | 35.18 | 3.43 | 11.27% | 0.00 | 14.95% | 423.36 | 0.89% | 0.45 | 43.52 |
| Lupin | 1,03,549.00 | 18.65 | 4.61 | 23.76% | 0.04 | 24.88% | 659.05 | 0.79% | 0.57 | 129.18 |
| Mankind Pharma | 1,00,137.00 | 48.43 | 6.14 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.44 | 49.37 |
| Dr. Reddy's Laboratories | 1,00,073.00 | 31.44 | 2.63 | 11.07% | 0.18 | 12.54% | 377.96 | 0.67% | 0.41 | 38.68 |
| Laurus Labs | 99,474.20 | 91.23 | 18.77 | 16.77% | 0.40 | 16.14% | 97.20 | 0.11% | 0.67 | 13.72 |
| Aurobindo Pharma | 96,700.60 | 26.06 | 2.55 | 9.25% | 0.19 | 11.76% | 391.14 | 0.24% | 0.38 | 41.58 |
BROOKS LABORATORIES Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹82.56 | ₹79.49 | ₹63.20 | ₹91.18 |
| Other Income | ₹0.88 | ₹0.92 | ₹0.21 | ₹0.80 |
| Total Revenue | ₹83.44 | ₹80.40 | ₹63.42 | ₹91.99 |
| Total Expenses | ₹80.25 | ₹78.85 | ₹98.83 | ₹115.88 |
| Profit Before Tax | -₹9.79 | -₹19.57 | -₹38.37 | -₹23.90 |
| Tax | ₹0.18 | ₹0.03 | -₹7.32 | -₹4.59 |
| Profit After Tax | -₹9.97 | -₹19.59 | -₹31.05 | -₹19.31 |
| EPS - Basic | -₹3.72 | -₹7.67 | -₹12.57 | -₹7.82 |
| EPS - Diluted | -₹3.72 | -₹7.67 | -₹12.57 | -₹7.82 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | -₹9.79 | -₹19.57 | -₹38.37 | -₹23.90 |
| Income before WC changes | ₹4.64 | ₹3.08 | -₹25.76 | -₹12.85 |
| Change in Assets | -₹1.71 | -₹3.78 | -₹0.33 | -₹12.62 |
| Change in Liabilities | -₹0.81 | -₹9.29 | ₹11.76 | -₹11.70 |
| Change in WC | -₹2.52 | -₹13.08 | ₹11.43 | -₹24.33 |
| Cash flow from Operations | ₹2.63 | -₹9.80 | -₹14.49 | -₹37.44 |
| Cash flow from Investing | -₹45.14 | ₹0.18 | ₹0.49 | -₹24.91 |
| Cash flow from Financing | ₹42.43 | ₹9.72 | ₹11.41 | ₹64.07 |
| Total Cash Flow | -₹0.08 | ₹0.10 | -₹2.58 | ₹1.72 |
| Cash (Start of the year) | ₹0.13 | ₹0.02 | ₹2.61 | ₹0.88 |
| Cash (End of the year) | ₹0.04 | ₹0.13 | ₹0.02 | ₹2.61 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹89.82 | ₹59.40 | ₹81.99 | ₹134.73 |
| Current Assets | ₹33.88 | ₹31.05 | ₹27.61 | ₹61.18 |
| Total Assets | ₹123.69 | ₹90.45 | ₹109.60 | ₹195.91 |
| Current Liabilities | ₹22.84 | ₹23.05 | ₹33.02 | ₹48.88 |
| Net Current Asset | ₹11.03 | ₹8.00 | -₹5.42 | ₹12.30 |
| Non-Current Liabilities | ₹2.75 | ₹1.81 | ₹2.62 | ₹12.71 |
| Equity Capital | ₹98.10 | ₹65.59 | ₹73.95 | ₹134.32 |
| Total Equity & Liabilities | ₹123.69 | ₹90.45 | ₹109.60 | ₹195.91 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹82.56 | ₹79.49 | ₹55.54 | ₹76.97 |
| Other Income | ₹0.88 | ₹0.92 | ₹0.12 | ₹0.95 |
| Total Revenue | ₹83.44 | ₹80.40 | ₹55.65 | ₹77.91 |
| Total Expenses | ₹80.21 | ₹78.85 | ₹63.84 | ₹77.25 |
| Profit Before Tax | ₹3.23 | ₹1.55 | -₹8.18 | ₹0.67 |
| Tax | ₹0.18 | ₹0.03 | ₹0.00 | ₹0.00 |
| Profit After Tax | ₹3.05 | ₹1.53 | -₹8.18 | ₹0.67 |
| EPS - Basic | ₹1.14 | ₹0.58 | -₹3.32 | ₹0.27 |
| EPS - Diluted | ₹1.14 | ₹0.58 | -₹3.32 | ₹0.27 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹3.23 | ₹1.55 | -₹8.18 | ₹0.67 |
| Income before WC changes | ₹4.64 | ₹3.08 | -₹5.43 | ₹3.10 |
| Change in Assets | -₹1.71 | -₹3.78 | ₹9.54 | -₹12.12 |
| Change in Liabilities | -₹0.81 | -₹9.29 | -₹3.37 | ₹12.40 |
| Change in WC | -₹2.52 | -₹13.08 | ₹6.17 | ₹0.29 |
| Cash flow from Operations | ₹2.63 | -₹9.80 | ₹0.55 | ₹3.12 |
| Cash flow from Investing | -₹45.14 | ₹0.18 | -₹0.40 | ₹1.12 |
| Cash flow from Financing | ₹42.43 | ₹9.72 | -₹0.21 | -₹4.23 |
| Total Cash Flow | -₹0.08 | ₹0.10 | -₹0.06 | ₹0.02 |
| Cash (Start of the year) | ₹0.13 | ₹0.02 | ₹0.08 | ₹0.06 |
| Cash (End of the year) | ₹0.04 | ₹0.13 | ₹0.02 | ₹0.08 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹106.78 | ₹63.34 | ₹64.82 | ₹66.42 |
| Current Assets | ₹33.88 | ₹31.05 | ₹27.61 | ₹37.04 |
| Total Assets | ₹140.66 | ₹94.39 | ₹92.42 | ₹103.45 |
| Current Liabilities | ₹22.84 | ₹23.05 | ₹33.02 | ₹35.46 |
| Net Current Asset | ₹11.03 | ₹8.00 | -₹5.42 | ₹1.57 |
| Non-Current Liabilities | ₹2.75 | ₹1.81 | ₹2.62 | ₹2.99 |
| Equity Capital | ₹115.07 | ₹69.53 | ₹56.78 | ₹65.00 |
| Total Equity & Liabilities | ₹140.66 | ₹94.39 | ₹92.42 | ₹103.45 |
| 13 Aug | 0L |
|---|---|
| 12 Aug | 0L |
| 11 Aug | 0L |
| 10 Aug | 0L |
| 7 Aug | 0L |
| Average | 0L |
Popular Stocks
BROOKS LABORATORIES Share Price FAQs
What is BROOKS LABORATORIES share price today?
BROOKS LABORATORIES share price is ₹65.60 as on 13 Aug, 2026, 15:24 IST.
How has the BROOKS LABORATORIES share price performed in the past?
In the last 1 year, BROOKS LABORATORIES delivered a return of -58.01%. The BROOKS LABORATORIES share price hit a high of ₹164.02 and low of ₹36.30.
How much is the Mutual Fund shareholding in BROOKS LABORATORIES shares?
The Mutual Fund Shareholding in BROOKS LABORATORIES was 9.90% at the end of Jun 2026.
What is the the 52-week high and low of BROOKS LABORATORIES shares ?
The 52-week high and low of BROOKS LABORATORIES share is ₹164.02 and ₹36.30 as of 13 Aug, 2026.
What is the market cap of BROOKS LABORATORIES?
The market capitalisation of BROOKS LABORATORIES is ₹185.58 Crores as on 13 Aug, 2026.
What are the stock symbols of BROOKS LABORATORIES?
The stock symbol of BROOKS LABORATORIES is BROOKS on the NSE, 533543 on the BSE, and the ISIN is INE650L01011.
What was yesterday's closing price of BROOKS LABORATORIES shares ?
BROOKS LABORATORIES shares closed yesterday at ₹62.48 on NSE & ₹63.00 on BSE
How to buy BROOKS LABORATORIES shares?
To buy BROOKS LABORATORIES shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy BROOKS LABORATORIES shares on Holidays?
No, shares of BROOKS LABORATORIES or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell BROOKS LABORATORIES shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of BROOKS LABORATORIES?
The PE and PB ratio of BROOKS LABORATORIES is 7.54 and 1.51 respectively, as on 13 Aug, 2026, 15:24 IST.